AALL0631: A Phase III Study of Risk Directed Therapy for Infants with ALL: Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431)/ Therapy for New Diagnosis Very High Risk Disease- Conditions:
Cancer - Leukemia and Lymphoma,
Medications
- Gender:
Female,
Male
PrimaryTo compare the 3-year event-free survival of infants with mixed lineage leukemia rearranged (MLL-R) acute lymphoblastic leukemia (ALL) randomized to treatment with a modified P9407 chemotherapy backbone with or without the FLT3 inhibitor lestaurtinib. Secondary1. To determine a safe, tolerab...
More
AAML05P1: Phase II Pilot Study of Killer Immunoglobulin-Like Receptor-Incompatible Unrelated Donor Hematopoietic Cell Transplantation in Young Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia/ Therapy for New Diagnosis High Risk Disease- Conditions:
Adult Studies,
Cancer - Leukemia and Lymphoma,
Medications
- Gender:
Female,
Male
1. To define the relationship between the status of donor NK-cell receptor and patient outcomes after killer immunoglobulin-like receptor-incompatible unrelated donor (URD) hematopoietic cell transplantation (HCT) in young patients with poor prognosis relapsed or refractory acute myeloid leukemia ...
More
AAML0631: Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox IND #103331) During Consolidation/ Therapy for New Diagnosis High Risk- Conditions:
Adult Studies,
Cancer - Leukemia and Lymphoma,
Medications
- Gender:
Female,
Male
Primary To decrease the total anthracycline dose from the best current published results in patients with standard-risk childhood acute promyelocytic leukemia (APL) while still maintaining a comparable event-free survival (EFS) Secondary To assign treatment based on risk stratification by WBC at di...
More
ARST08P1: A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination With Intensive Multi-Agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma- Conditions:
Adult Studies,
Cancer - Musculoskeletal Tumors,
Medications
- Gender:
Female,
Male
This clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. ...
More
ADVL0413: A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias- Conditions:
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. ...
More
ADVL0911: A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features- Conditions:
Cancer - Kidney Tumors,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects and best dose of Seneca Valley virus-001 in treating young patients with relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features. ...
More
ADVL0921: A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children With Recurrent / Refractory Solid Tumors and Leukemia- Conditions:
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Medications
- Gender:
Female,
Male
This phase II trial is studying the side effects of and how well Alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. ...
More
Study to Test Safety of a Virus Therapy Children / Young Adults- Conditions:
Adult Studies,
Cancer - Hemangioma and Vascular Malformation,
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Cancer - Musculoskeletal Tumors,
Cancer - Neurofibromatosis Tumors,
Medications,
Vaccines
- Gender:
Female,
Male
Cincinnati Children’s Hospital Medical Center is conducting a research study, sometimes known as a clinical trial or clinical study, to test how safe and well tolerated the study drug is in children and young adults with certain cancers. Researchers want to see what effects - good or bad - the stu...
More
Phase II Study of Paclitaxel, Ifosfamide and Carboplatin - Conditions:
Cancer - Kidney Tumors
- Gender:
Female,
Male
Primary Determine the response rate in pediatric patients with recurrent or resistant malignant germ cell tumors treated with paclitaxel, ifosfamide, and carboplatin. SecondaryDetermine the toxicity of this regimen in these patients. Projected Accrual A total of 20 patients will be accrued for this...
More
ADVL0912: A Phase I/II study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in children with Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma- Conditions:
Cancer - Brain and Spinal Tumors,
Cancer - Kidney Tumors,
Cancer - Leukemia and Lymphoma,
Cancer - Liver Tumors,
Cancer - Musculoskeletal Tumors,
Cancer - Neuroblastoma,
Cancer - Retinoblastoma,
Medications
- Gender:
Female,
Male
This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. ...
More
